GLP1R and Hypoglycemia: Consistent with the GLP-1 RAs’ mechanism of action, treatment with dulaglutide also has been associated with alterations of other additional parameters that may be implicated in modifying CV risk including lower risk of hypoglycemia [39], body weight loss [39], and a small decrease in SBP [17].